Corvus Pharmaceuticals announced new preclinical data on November 9, 2024, highlighting the potential of ciforadenant, its adenosine A2A receptor antagonist, to overcome resistance to anti-PD1 immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). The data was presented in an oral session at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting.
Studies identified SPP1+ myeloid cells as a critical mediator of immunotherapy resistance in mCRPC, with adenosine signaling through the adenosine 2A receptor playing a role. In a murine model, ciforadenant inhibited adenosine signaling, leading to increased CD8+ T cell infiltration and reduced tumor growth.
This preclinical evidence supports ciforadenant's mechanism of action and its potential to address a significant unmet medical need in mCRPC, a condition often resistant to current checkpoint inhibitors. The findings also suggest the potential for an adenosine gene signature to identify patients most likely to respond, which could optimize future clinical trial designs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.